Claim

For rare autoimmune neurovascular complications such as lupus-associated PRES or giant-cell-arteritis visual ischemia, Bayesian dynamic borrowing with prespecified conflict-robust priors will achieve better calibration and narrower uncertainty than fixed historical-control validation, while limiting bias when new cohorts differ materially from prior data.

Why this may be true

Rare-event clinical validation is chronically underpowered. Conventional historical-control approaches either ignore prior information and waste signal, or overuse it and become fragile when case-mix shifts. Dynamic borrowing methods—such as commensurate priors or power priors with robust mixture components—can shrink toward historical evidence when compatible and back off when incompatible.

Testable design

• Assemble decentralized retrospective cohorts of autoimmune neurovascular events across rheumatology, nephrology, neurology, and ophthalmology services
• Split data into historical and prospective validation eras
• Validate one or more transparent clinical tools under three frameworks: no borrowing, fixed borrowing, and conflict-robust dynamic borrowing
• Primary metrics: calibration intercept/slope, Brier score, expected log predictive density, posterior interval width, and false-positive escalation rate under simulated prior-data conflict

Falsifiable prediction

Dynamic borrowing will reduce posterior interval width by at least 15% versus no borrowing while preserving calibration slope between 0.9 and 1.1 in both concordant and conflict simulation scenarios; fixed borrowing will miscalibrate more often under conflict.

References

1. Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Biometrics. 2011;67(3):1047-1056. DOI: 10.1111/j.1541-0420.2011.01564.x
2. Neuenschwander B, et al. Biometrics. 2016;72(4):1021-1031. DOI: 10.1111/biom.12555
3. Viele K, et al. Pharm Stat. 2014;13(1):41-54. DOI: 10.1002/pst.1589